Sanofi Pasteur, Discovery Drive, Swiftwater, PA 18370, USA.
Vaccine. 2012 Jun 19;30(29):4307-9. doi: 10.1016/j.vaccine.2012.01.056.
Clostridium difficile has become the most frequent hospital-acquired infection in North America and the EU. C. difficile infection (CDI) is present worldwide and disease awareness is increasing. In the US, EU, and Canada, in addition to hospital diagnosed disease, CDI has also been reported with increasing frequency in the community. Hypervirulent strains have increased the morbidity and mortality associated with CDI. Current treatment options are suboptimal. Of all patients treated for CDI, 20% relapse and 65% of those experiencing a second relapse become chronic cases. An association between increased serum levels of IgG antibody against toxin A and asymptomatic carriage of C. difficile provides a rationale for vaccine development. Sanofi Pasteur's C. difficile candidate vaccine is being developed for the prevention of primary disease. The target population is adults at risk of CDI, those with planned hospitalization, long-term care/nursing home residents, and adults with co-morbidities requiring frequent/prolonged antibiotic use.
艰难梭菌已成为北美和欧盟最常见的医院获得性感染。艰难梭菌感染（CDI）在全球范围内存在，且疾病意识正在提高。在美国、欧盟和加拿大，除了医院诊断的疾病外，CDI 在社区中也越来越频繁地被报道。高毒力菌株增加了与 CDI 相关的发病率和死亡率。目前的治疗选择并不理想。在所有接受 CDI 治疗的患者中，20%会复发，而 65%经历第二次复发的患者会成为慢性病例。针对毒素 A 的 IgG 抗体血清水平升高与无症状艰难梭菌携带之间的关联为疫苗开发提供了依据。赛诺菲巴斯德的艰难梭菌候选疫苗正在开发中，用于预防原发性疾病。目标人群是有 CDI 风险的成年人、计划住院的成年人、长期护理/疗养院居民以及患有需要频繁/长期使用抗生素的合并症的成年人。
